M2 EQUITYBITES-June 11, 2019-The US FDA approves the first chemoimmunotherapy regimen Polivy with BR for patients with relapsed or refractory diffuse large B-cell
Patients with relapsed large B-cell
lymphoma in the two-year follow-up of ZUMA-1 were analyzed in two groups those 65 years or older (?65) (n=24) and those younger than 65 years (
This therapy is comprised of Nordic Nanovector's chimeric anti-CD37 antibody (NNV003) and the alpha-particle-generator lead-212 (212Pb) for the treatment of B-cell
Grey Zone Lymphoma, Unclassifiable With Features Intermediate Between Diffuse Large B-Cell
Lymphoma and Classical Hodgkin Lymphoma: Better Results With CHOP-Like Regi mens.
The age-adjusted international prognostic index score calculation significantly influences the overall survival in patients with relapsed/refractory diffuse large B-cell
The neoplastic lymphocytes in PCFCL express B-cell
markers (CD19, CD20, CD22, CD79a, PAX5) and at least one follicle center marker, which is usually BCL6 or, less commonly, CD10 (Figure 2, D and E).
This retrospective study aimed to identify the frequency of HBV reactivation and the predictive factors in patients with resolved HBV infection who were treated with a chemotherapy regime containing rituximab for B-cell
epitopes can be identified by different methods including solving the 3D structure of antigen-antibody complexes, peptide library screening of antibody binding or performing functional assays in which the antigen is mutated and the interaction antibody-antigen is evaluated [3, 4].
If approved, Kymriah would represent the first chimeric antigen receptor T cell (CAR-T) therapy available for two distinct indications in non-Hodgkin lymphoma and B-cell
IVLBCL is a rare type of extranodal large B-cell
lymphoma first described in 1959 by Pfleger and Tappeiner .
There is a validated prognostic model to predict the risk of CNS relapse utilizing five clinical factors (age > 60 years, LDH > normal, stage III or IV, ECOG PS >1, and involvement of the kidney or adrenal gland) thus recommending for CNS prophylaxis therapy.10,11 Risk of CNS relapse is higher in activated B-cell
(ABC) than germinal center B-cell
(GCB).12,13 Addition of rituximab to chemotherapy (CHOP) may improve the remission rate and overall survival of patients with DLBCL.
Subjects and methods: Using whole blood samples from 53 patients with B-cell
malignancies and 15 apparently healthy subjects, miR-155 was extracted and profiled by quantitative real-time PCR (RT-qPCR).